1	SHERLOCK4HAT: a CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis
2	
3	HAT diagnosis by SHERLOCK
4	N( $\frac{1}{2}$ A $\frac{1}{2}$ A $\frac{1}{2}$ being the set of $\frac{1}{2}$ D being $\frac{1}{2}$ D
5	Nuria Sima <sup>7</sup> , Annick Dujeancourt-Henry, Blanca Linana Periaza, Marie-Noelle Ungeneuer, $Price Potymous^{2,3}$ ** and Lucy Clover <sup>1</sup> **
6 7	Blice Rotureau 1* and Lucy Glover 1*.
8	<sup>1</sup> Institut Pasteur, Université de Paris, Trypanosome Molecular Biology Unit, Department of
9	Parasites and Insect Vectors, Paris, France.
10	<sup>2</sup> Institut Pasteur, Université Paris Sorbonne, Trypanosome Transmission Group, Trypanosome
11	Cell Biology Unit, INSERM U1201 & Department of Parasites and Insect Vectors, Paris, France.
12	<sup>3</sup> Institut Pasteur of Guinea, Parasitology Unit, Conakry, Guinea.
13	<sup>4</sup> Institut Pasteur, ICAReB platform (Clinical Investigation & Access to Research Bioresources)
14	of the Center for Translational Science, Paris, France.
15	† Co-last authors
16	
17	* To whom correspondence should be addressed lucy.glover@pasteur.fr, Tel: +33 140613425;
18	brice.rotureau@pasteur.ir, 1ei: +55 140615855.
20	Keywords: Trypanosoma brucei HAT diagnostic SHERLOCK
21	
22	
23	
22	
25	
26	
20	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	

#### 39 Abstract

#### 40

Elimination of Human African Trypanosomiasis (HAT) requires highly specific and sensitive 41 tools for both diagnostic at point of care and epidemiological surveys. We have adapted 42 SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for the detection of 43 trypanosome nucleic acids. Our SHERLOCK4HAT diagnostic tool kit, using 7SLRNA, TgSGP 44 and SRA targets, distinguishes between Trypanosoma brucei (T. b.) brucei, T. b. gambiense (g) 45 and T. b. rhodesiense (r) without cross-reactivity and with sensitivity between 0.01 and 0.1 46 47 parasite/µL. SHERLOCK4HAT can accurately detect a trypanosome infection in cryo-banked 48 patient buffy coats, with 85.1% sensitivity and 98.4% specificity for gHAT, and 100% sensitivity and 94.1% specificity for rHAT. Our SHERLOCK4HAT diagnostic showed 85.6% correlation 49 with a reference standard qPCR in gHAT patients, 96.2% correlation in rHAT patients, 50 discriminates between r/gHAT with 100% accuracy and is compatible with lateral flow assay 51 readout for use at the point of care. 52

- 53
- 54

#### 55 Introduction

Human African Trypanosomiasis (HAT), or sleeping sickness, is endemic to sub-Saharan 56 countries and without prompt diagnosis and treatment, is usually fatal (1). It is caused by a tsetse-57 borne infection with protist parasites: Trypanosoma brucei (T. b.) gambiense (gHAT), which 58 represents 85% of the new cases and is endemic to central and western Africa, and T. b. 59 rhodesiense (rHAT) which is responsible for the remaining 15% and is found in southern and 60 eastern Africa. Due to both vector control, mass screening and treatment of those infected, the 61 number of gHAT cases is decreasing, and has been maintained below 1,000 new gHAT cases / 62 year since 2018 (2). In this context, gHAT has been included in the WHO roadmap to elimination, 63 with zero transmission by 2030 (2). Because of the preference of T. b. rhodesiense for the animal 64 reservoir and the scarcity of control tools, the complete elimination of rHAT is not considered to 65 be feasible. 66

The current diagnostic algorithms for gHAT rely on an initial serological test, followed by a 67 parasitological confirmation by direct observation under microscope, which is time consuming, 68 requires trained staff and specialized equipment, and presents a suboptimal diagnostic sensitivity. 69 70 The reduction in gHAT cases has brought about new challenges, not least that the positive predictive value of any diagnostic test diminishes as the disease burden is reduced. This has been 71 already observed with the gHAT serological tests, the classical Card Agglutination Test for 72 Trypanosomiasis (CATT) and the more recently developed rapid diagnostic tests (RDTs) (review 73 in (3, 4)). Moreover, these tests are based on specific surface antigens, which if poorly or not 74 expressed, can lead to missed diagnoses. No serological diagnostic tools are available for rHAT, 75 and diagnosis is still based on clinical manifestations and visual detection of parasites by 76 microscopy. Several molecular amplification tests have been developed for gHAT with promising 77 results (18SrDNA-PCR, TBR-PCR, Tb177bp-qPCR, 18SrDNA-qPCR, SLRNA RT-qPCR, 18S 78 79 RNA RT-qPCR, RIME-LAMP) (review in (3, 4)) but their applications for mass screening are limited due to cost and required infrastructure. Importantly, diagnosis of gHAT is further 80 complicated as there is increasing evidence that the traditional parasitological approaches fail to 81 detect T. b. gambiense infections among 'asymptomatic' seropositive individuals who are 82 83 apparently able to control infection to low levels and / or to maintain extravascular parasites, especially in the skin, in the absence of detectable blood parasitemia (5). Not only may these 84 individuals contribute to transmission, but they may potentially go on to develop clinical gHAT 85 (5-7). Ultimately, specific and high-sensitive tools, suitable for point-of-care (PoC) diagnosis and 86 / or usable in a high-throughput mode in low-income countries are needed. 87

Adaptation of CRISPR technology towards the development of molecular diagnostics has led to 88 highly sensitive and specific tools for the detection of *Plasmodium* (8, 9), Zika, Dengue, SARS-89 90 CoV-2, Ebola and *Mycobacterium tuberculosis* to name a few (10). SHERLOCK (for Specific High-sensitivity Enzymatic Reporter unLOCKing) is a CRISPR-based approach that relies on the 91 programable collateral nuclease activity of Cas enzymes to identify specific nucleic acid (NA) 92 sequences in samples (11, 12). Here, we describe the development of a point-of-care applicable, 93 highly sensitive and specific diagnostic tool that can discriminate between trypanosome species 94 95 causing g- and rHAT. Our SHERLOCK4HAT tool kit, meets the current WHO recommendations for gHAT diagnostic, and we show its exquisite sensitivity and specificity using RNA from cultured parasites, simulated infections and cryo-banked patient samples.

## 98 **Results**

#### 99 Selection of *Trypanosoma* target regions

The SHERLOCK workflow combines isothermal recombinase polymerase amplification (RPA) 100 with highly specific Cas13-CRISPR RNA target recognition coupled to readout via plate reader 101 (for mass screening) or lateral flow strip (for PoC diagnosis) (Fig. 1A) (12, 13). To adapt 102 SHERLOCK for the detection of T. brucei sp., we selected gene targets based on the following 103 criteria (i) genes expressed in the human infective form of the parasites, (ii) T. brucei species- or 104 subspecies-specific, (iii) degree of conservation between different strains and (iv) few to no single 105 nucleotide polymorphisms (SNPs) (11, 14). We assessed several candidate genes, including the 106 superoxide dismutase B1 (SODB1) gene (Tb927.11.15910), the component of the peptide 107 recognition particle, 7SLRNA (Tb927.8.2861), the T. b. gambiense-specific glycoprotein gene 108 (TgSGP; FN555988.1) and the T. b. rhodesiense-specific serum resistance associated gene (SRA; 109 AF097331). BLAST analysis revealed that the SODB1 gene sequence is highly conserved 110 between the Trypanozoon subgenus with 99% identity (T. b. rhodesiense sequence was not 111 available) and shared certain degree of homology with T. cruzi and Leishmania donovani genes 112 (77.92% and 76.68% identity, respectively) (data file S1). The 7SLRNA is highly conserved 113 within the Trypanozoon taxa, with 99% identity shared between the T. brucei sp., but more distant 114 to the co-endemic species T. congolense and T. vivax with 86.31% and 79.77% identity 115 respectively (data file S1). TgSGP gene is specific to Group 1 T. b. gambiense and conserved 116 across isolates in endemic territories (15-17). TgSGP-like genes, closely related to a possible 117 ancestor VSG gene (Tb10.v4.0178), have been identified in other T. brucei sspp., with the 5' 118 region of the genes particularly conserved (16, 17). SRA is specific to T. b. rhodesiense and 119 provides an unbiased identification of the parasite (18–24). Nevertheless, SRA is a VSG-like gene 120 (18) and the first 400 bp share 81% identity with a possible ancestor gene present in the T. b. 121 brucei genome (Tb927.9.17380) (25). Three SRA sequence variants (AF097331, AJ345057, 122 AJ345057) have been identified from field isolates with homology from 97.9-99.7% (22, 23, 26) 123 (fig. S1). To develop a pan-Trypanozoon SHERLOCK diagnostic, RPA primers and CRISPR 124 RNA guides (crRNAs) were designed to cover the conserved regions of the 7SLRNA and SODB1 125 genes in the Trypanozoon subgenus, that are distinct to the other trypanosomatids. For a T. b. 126 gambiense and T. b. rhodesiense specific SHERLOCK diagnostic, guides were designed to the 127 variable regions of TgSGP and SRA genes. In an attempt to ensure our tests would be applicable 128 across a wide range of field isolated strains, identified SNPs were considered and guides were 129 designed outside of these regions (tables S1 and S2). 130

#### 131 SHERLOCK distinguishes between the three *T. brucei* subspecies with high sensitivity

We focused on developing a SHERLOCK diagnostic for the two subspecies of *T. brucei* that cause HAT. We screened several RPA primer pairs and crRNA combinations for each of the selected target genes (fig. S2 and table S1 and S3). For *7SLRNA* target, 3 RPA amplicons (Ampl) were combined with 4 crRNA candidates (Ampl 1:crRNAb1-b3, bs, Ampl 2:crRNAb1-b3, Ampl

3:crRNAb1-b3, bs); for SODB1 target, 6 RPA amplicons and 15 crRNA candidates were studied 136 (Ampl 1:crRNA 1.1-1.3, Ampl 2:crRNA 2.1-2.2, Ampl 3:crRNA 3.3, Ampl 4:crRNA 4.1-4.3, 137 Ampl 5:crRNA 5.1, 5.3, Ampl 6:crRNA 6.1-6.4); 8 RPA amplicons and 23 crRNA were tested 138 for TgSGP (Ampl 1:crRNA 1.1-1.3; Ampl 2:crRNA 2.1-2.3; Ampl 3:crRNA 3.1-3.3, Ampl 139 4:crRNA 4.1-4.3, Ampl 5:crRNA 5.1, 5.3, Ampl 6:crRNA 6.1-6.3, Ampl 7:crRNA 7.1-7.3, Ampl 140 8:crRNA 8.1-8.3); and 5 RPA amplicons and 14 crRNA were assessed for SRA (Ampl 1:crRNA 141 1.1-1.3, Ampl 2:crRNA 2.1-2.2, Ampl 4:crRNA 4.1-4.3, Ampl 5:crRNA 5.1-5.3, Ampl 8:crRNA 142 8.1-8.3) (fig. S2A and table S3). A single RPA amplicon-crRNA combination was selected for 143 each gene target based on highest signal-to-noise ratio (fig. S2A) and specificity (fig. S2B) when 144 compared to target recognition in two co-endemic parasite species Leishmania major and 145 *Plasmodium falciparum* and to human embryonic kidney (HEK) T cells, as a representation of the 146 host. Based on sensitivity and specificity results, we selected single combination of RPA primers 147 and crRNA sequences for 7SLRNA, TgSGP and SRA for all subsequent analyses (Fig.1B and 148 Table 1). Exquisite specificities were shown for *7SLRNA* as a pan-*Trypanozoon* diagnostic target, 149 and  $T_gSGP$  and SRA as species-specific diagnostic targets for T. b. gambiense and T. b. 150 rhodesiense, respectively (Fig. 1C). The 7SLRNA SHERLOCK routinely outperformed the 151 SODB1 SHERLOCK, the second pan-Trypanozoon target, hence no further experiments were run 152 with the SODB1 target. We then wanted to determine the limit of detection (LoD) of each 153 SHERLOCK reaction. The SRA SHERLOCK already showed high sensitivity (Fig. 1D), and did 154 not require further optimisation. For the 7SLRNA and TgSGP SHERLOCK reactions, we tested 155 various RPA primer and Magnesium oxalacetate (MgOAc) concentrations (fig. S3), as both can 156 157 have a direct impact on the amplification rate, and thus on the amplification efficiency. For all subsequent analysis, 480 nM of RPA primer and 14 mM MgOAc were used in the 7SLRNA 158 SHERLOCK reaction and 240 nM RPA primer and 14 mM MgOAc in the TgSGP SHERLOCK 159 reaction (fig. S3). Using input RNA extracted from cultured parasites, the LoD for the 7SLRNA 160 and TgSGP targets was determined to be 0.1 parasite/ $\mu$ L, and the LoD for SRA target was 0.01 161 parasite/µL, which falls within the range of parasitemia commonly observed in HAT patients 162 (Fig. 1D) (27, 28). Using in vitro transcribed RNA, the LoD was calculated to be 200 aM (100 163 molecules/µL) for 7SLRNA and TgSGP, and 20 aM (10 molecules/µL) for SRA (fig. S4). This 164 analytical sensitivity is similar to that reported previously for other molecular diagnostics that are 165 subgenus specific (29-35) and 10 to 100-fold more sensitive to those reported for subspecies-166 specific tests (21, 36, 37). 167

#### 168 SHERLOCK can be adapted to a PoC diagnostic use

SHERLOCK is amenable to readout by lateral flow assay (LFA) (12). Importantly, using a 169 polyethylene glycol (PEG)-based CRISPR-optimized buffer (provided by Milenia Biotec), we 170 were able to detect the 7SLRNA, TgSGP and SRA SHERLOCK targets with the same respective 171 sensitivities as with the fluorescent readout, but with a reduced background signal as compared to 172 the commercially available LFA buffers, thereby reducing the ambiguity of the readout (Figs. 1E 173 and S5). Our SHERLOCK4HAT diagnostic kit is therefore compatible with use at the PoC. To 174 further optimize SHERLOCK4HAT for PoC use as a one-tube reaction (8, 38), we focussed on 175 the 7SLRNA target and modified the reaction components and conditions (fig. S6). Given that the 176 reverse-transcriptase (RT) and Cas13 activities have different temperature preferences, we 177

evaluated the performance of one-tube reactions at temperatures from  $37^{\circ}$ C to  $42^{\circ}$ C, and found 178 that reactions at 37°C had higher signal with reduced sample-to-result time (fig. S6A). An 179 additional consideration for the development of a PoC diagnosis for use in low-income countries 180 is affordability. We therefore tested three RT enzymes from different manufacturers and selected 181 ProtoScript II (NEB) as the most cost-effective reaction with a cost of  $2.5 \notin$  / reaction (fig. S6B). 182 Given that Cas13a has uridine-cleavage preference (12, 39), we compared RNase Alert with a 183 6U-FAM reporter. The signal intensity obtained with the 6U-FAM reporter was lower and was 184 more prone to spontaneous degradation, as seen with the non-template control reaction (fig. S6C). 185 Thus, we selected RNase Alert as a reporter for an optimized one-tube SHERLOCK diagnostic 186 187 and used 8  $\mu$ L of input material (fig. S6D). With these improvements, the 7SLRNA one-tube SHERLOCK reaction had similar sensitivity than the two-step reaction and detected 1 parasite/uL 188 in less than 1 h (Fig. 1, F and G). 189

# The SHERLOCK4HAT diagnostic kit can accurately detect a trypanosome infection across multiple regions and over extended periods of time

192 Genetic variability between field isolates can potentially lead to false negatives with molecular diagnostic. Therefore, the development of a robust diagnostic hinges upon the ability to detect all 193 parasite strains or variants. To demonstrate the robust specificity of our SHERLOCK4HAT 194 diagnostic kit, we analyzed total RNAs from 57 Trypanozoon strains, isolated from their host over 195 the course of 50 years and maintained at the Institute of Tropical Medicine (ITM, Antwerp, 196 Belgium) (40) (table S4). Using our two-step SHERLOCK assay, all samples were positive for 197 7SLRNA, confirming 7SLRNA SHERLOCK as a pan-Trypanozoon diagnostic and 198 epidemiological tool (Fig. 2 and table S4). Within this set, the 46 T. b. gambiense Group 1 199 mammalian stage isolates tested positive for TgSGP, and 3 out of 4 T. b. gambiense Group 1 200 201 insect stage isolates were negative, as expected since TgSGP is only expressed in the mammalian stage of the parasite (15). The single T. b. gambiense Group 1 insect stage isolate 202 (MHOM/CI/91/SIQUE1623) that was positive for TgSGP, may have retained low level 203 expression of the gene. The 7 non-Group 1 T. b. gambiense strains tested negative for TgSGP, 204 including the T. b. gambiense Group 2 sample (Fig. 2, and table S4), thus confirming the 205 diagnostic specificity of the TgSGP SHERLOCK for T. b. gambiense Group 1. The two T. b. 206 rhodesiense strains included in the collection were positive for SRA, and 54 of the 55 non-T. b. 207 rhodesiense strains tested negative for SRA (Fig. 2 and table S4). A single isolate, AnTat 22.1, 208 classified as T. b. gambiense Group 1 was positive for both TgSGP SHERLOCK and SRA 209 SHERLOCK (table S4). Sequence analysis showed that the SRA SHERLOCK target amplicon 210 shared 83.3% identity with a VSG (Tbb1125VSG-4336, accession number: KX700900) that was 211 expressed in this sample (fig. S7A). There are 7 nucleotide mismatches between the SRA guide 212 and the homologous region in the VSG sequence (fig. S7B), and this is the most likely source of 213 the cross-reactivity. In spite of the 1.8% cross-reactivity observed with the SRA SHERLOCK 214 within the group of samples analyzed, 100% of the strains were detected with the corresponding 215 test, confirming the use of TgSGP SHERLOCK and SRA SHERLOCK for diagnosis across 216 endemic regions. 217

#### 218 SHERLOCK4HAT detects trypanosomes in dried blood spots, whole blood and buffy coat

There is a critical need for highly sensitive and specific molecular detection tools that can be use 219 in a high-throughput format in the context of gHAT post-elimination phase. Adapted strategies 220 will be adopted to monitor for potential residual transmission and these tests will be performed in 221 regional reference centres. Methods to capture individual samples, such as dried blood spots 222 223 (DBSs) would allow easy collection in the field and safe transport and storage back to a lab. SHERLOCK can detect both DNA and RNA, therefore, working with total nucleic acid (TNA) 224 instead of RNA alone can increase the sensitivity. However, for use as a test of cure it is 225 important to work with RNA only, since trypanosome DNA has been detected in the host up to 2 226 years after cure (35). To optimize the 7SLRNA SHERLOCK for epidemiological surveys, we 227 compared three methods of TNA extraction from DBS using non-infected sheep blood spiked 228 with cultured *T. brucei* parasites spotted on Whatman 903<sup>TM</sup> Cards. Our *7SLRNA* SHERLOCK 229 was able to detect 100 parasites/µL using a RNeasy kit (Oiagen) and 10 parasites/µL with the 230 NucleoSpin Triprep kit (Macherey-Nagel) (fig. S8A). We saw consistently greater sensitivity with 231 the NucleoSpin Triprep kit, and therefore used it for subsequent extractions from DBSs. Mass 232 screening campaigns are expected to result in a high volume of samples that require subsequent 233 processing, thus, an automated system that minimizes the hands-on time in the extraction process 234 and the cross-contamination between samples is preferred. We compared the performance of two 235 different kits from the automated, paramagnetic beads-based system Maxwell RSC (Promega) 236 and the manual column-based system from Qiagen (fig. S8, B and C). Maxwell RSC DNA blood 237 kit was more efficient than Maxwell RSC RNA kit for TNA extraction using simulated infected 238 samples and showed no cross-contamination, in contrast to the manual column-base kit (fig. S8, B 239 and C). Using simulated human infections (un-infected human blood spiked with T. brucei 240 parasites), we compared the performance of the 7SLRNA SHERLOCK using DBS, whole blood 241 and buffy coat. 7SLRNA SHERLOCK detected trypanosome TNAs equivalent to 1 parasite/µL in 242 the three types of samples (Fig. 3A), which is in line with the analytical sensitivity reported 243 previously with the M18S-qPCR in DBS (31). To determine the 7SLRNA SHERLOCK analytical 244 sensitivity, we analyzed 3 independent dilution series of simulated infections in whole blood and 245 buffy coat samples and estimated the LoD to be the lowest concentration where 3 out of 3 246 samples tested positive (Fig. 3, B and D). Here, the resulting analytical sensitivity was determined 247 to be 10 parasites/µL in whole blood and 1 parasite/µL in buffy coat. This is consistent with thet 248 increased sensitivity seen with the mini-anion exchange centrifugation technique (mAECT) when 249 buffy coat is analyzed instead of whole blood (27). We further resolved the analytical sensitivity 250 of the 7SLRNA SHERLOCK with buffy coat by analysing 20 replicates of simulated infected 251 samples at 0.66X, 1X or 1.5X a 1 parasite/µL parasitemia. We confirmed the 7SLRNA 252 SHERLOCK buffy coat LoD to be 1 parasite/µL in 95% of the samples detected (Fig. 3, C and 253 D). Further improvement of the extraction methods will be required to increase the analytical 254 sensitivity, since the LoD of SHERLOCK tests with RNA from cultured parasites was more 255 sensitive (Fig. 1D). 256

#### 257 Validation of the SHERLOCK4HAT diagnostic kit using clinical samples

To validate SHERLOCK4HAT as a diagnostic tool kit, we used samples obtained from the WHO HAT specimen biobank (*41*): 98 buffy coat samples from patients with confirmed gHAT; 48

buffy coat samples from gHAT endemic regions, but negative for gHAT, to act as controls; 19

buffy coat samples from patients with confirmed rHAT, and 20 buffy coat samples from rHAT 261 endemic regions, but negative for rHAT, as further negative controls. Additionally, we analyzed 262 14 buffy coat samples from un-infected donors from non-endemic regions. As a positive control 263 for TNA extraction to validate negative SHERLOCK results in clinical samples, i.e. to ensure that 264 265 no SHERLOCK inhibitors were remaining in the sample, we designed an additional SHERLOCK assay that targeted the human RNase P gene and validated its performance using RNA from 266 cultured human cells and parasites (fig. S9). All samples were maintained at -80°C from 267 collection until delivery by the WHO HAT specimen biobank, and all the samples tested here 268 were more than 10 years old and stored without any preservative (41). Therefore, the likelihood of 269 TNA deterioration was high, especially for RNA. As an additional control, we ran a *Tb177 bp* 270 repeat qPCR (32) in parallel. Trypanosome DNA was detected by qPCR in 47 out of 98 271 confirmed gHAT samples, suggesting deterioration of the TNAs in most of the samples (Fig. 4, A 272 and B and data file S2). Notably, the 7SLRNA SHERLOCK detected 55 out of 98 confirmed 273 gHAT samples, showing a higher sensitivity as compared to the reference qPCR test. The 274 concordance between the two assays was 85.6%, with 40 out of 47 qPCR positive samples and 97 275 out of 113 qPCR negative samples, positive and negative for SHERLOCK respectively (Fig. 4, A 276 and B and data file S2). Importantly, 15 of the 16 qPCR negative samples that tested positive for 277 SHERLOCK were part of the originally confirmed gHAT cohort, revealing our SHERLOCK 278 diagnostic to be more sensitive than the qPCR test (Fig. 4, A and B and data file S2). None of the 279 gHAT endemic negative control samples tested positive, and one out of 14 non-endemic negative 280 control samples was positive using the 7SLRNA SHERLOCK with an overall specificity of 281 98.4%. The sensitivity of the 7SLRNA SHERLOCK was 85.1 % for gHAT, based on the qPCR 282 positive samples (Fig. 4B). The TgSGP SHERLOCK detected 42.5% of the qPCR positive 283 samples with 88.7% specificity (data file S2 and table S5). These differences in sensitivity 284 between the spp-specific and the pan-Trypanozoon SHERLOCK are most probably due to a 285 selective degradation of the target RNAs. All 19 confirmed rHAT patient samples tested positive 286 for 7SLRNA SHERLOCK with 100% sensitivity and 94.1% specificity (Fig. 4, C and D and data 287 file S2). To note, the impact of TNA deterioration in these samples may be lower due to the 288 higher parasitemia in T. b. rhodesiense infections (1), seen here by the lower qPCR Ct values in 289 rHAT samples compared to those in gHAT samples (Fig. 4, A and C and data file S2). The SRA 290 SHERLOCK detected 79% of the qPCR positive samples with 100% specificity (data file S2 and 291 table S5). The combination of results from the 7SLRNA, TgSGP and SRA SHERLOCK 292 diagnostics suggests an increased sensitivity of the single tests, but slightly reduced specificity 293 (Fig. 4, B and D and table S5). No correlation between the stages of the disease and the qPCR Ct 294 values or the SHERLOCK fluorescence readouts in gHAT patients was observed (Fig. 4A and 295 data file S2). Results of the 19 confirmed rHAT samples with TgSGP SHERLOCK were 296 negative. Likewise, 20 selected confirmed gHAT samples were all negative when run using the 297 SRA SHERLOCK diagnosis protocol (Fig. 4E). Thus, the TgSGP and SRA SHERLOCK in patient 298 samples accurately discriminate between T. b. gambiense and T. b. rhodesiense infections. 299

#### 300 **Discussion**

301 Here we described the development of a new molecular detection tool for HAT diagnosis adapted

302 for use at a PoC and for HAT epidemiological surveillance. Our SHERLOCK4HAT diagnostic

can distinguish between the three *T. brucei* subspecies using a pan-*Trypanozoon*, *gambiense*specific, or *rhodesiense*-specific targets. Although our subspecies-specific targets use TgSGP and *SRA*, which are related to *VSG* genes, we do not see cross reactivity. In fact, in spite of the degree of DNA sequence homology shared between *SRA* and *VSG* variants, we saw no false positives, confirming that the selected target meets the specificity requirements for rHAT diagnosis.

As an RNA based diagnostic, SHERLOCK4HAT is a highly sensitive detection method for on-308 going infections with a simple set up. We show that the analytical sensitivity of 309 SHERLOCK4HAT for the Trypanozoon target is 0.1 parasite/µL (100 parasites/mL), which is 310 comparable to several molecular techniques for detection of Trypanozoon taxa (TBR-PCR/qPCR 311 and 18S-PCR, 50-100 parasites/mL). However, implementation of these techniques is limited by 312 the need for sophisticated equipment (29, 31, 32, 42). An additional advantage of 313 SHERLOCK4HAT is the single temperature isothermal RPA amplification coupled to a Cas13 314 detection, making our method more adapted to the low-income countries where the disease is 315 endemic. Other isothermal approaches have been developed with similar sensitivities to 316 SHERLOCK (LAMP-100 parasites/mL, NASBA-10 parasites/mL) (43, 44), but significant 317 infrastructure costs have limited their implementation in control programs. Our subspecies-318 specific SHERLOCK4HAT diagnostics using a TgSGP or SRA target are 10 to 100-fold more 319 sensitive than that the current subspecies-specific diagnostics using PCR/qPCR (21, 36, 45) and 320 show no overlap between the signal in positive and negative samples, resolving any ambiguity 321 seen in PCR and qPCR. In fact, our results indicated that SHERLOCK4HAT can unequivocally 322 discriminate between TgSGP and SRA, and therefore diagnose of T. b. gambiense and T. b. 323 rhodesiense infections. 324

The current gHAT field-applicable diagnostic algorithms are based on antibody detection in 325 patient blood (CATT and RDTs) with confirmation of seropositive cases by parasitological 326 327 observation (1, 4). These methods present some limitations: (i) false-negative results if the VSG variants detected by the test are poorly or not expressed (46), (ii) reduced specificity (1, 4), and 328 (iii) relatively high cost (RDTs), significant workload (CATT on serial plasma dilution, time at 329 microscope) and need for specialized staff and equipment (especially for parasitological 330 confirmation). For rHAT, no field-applicable diagnostic methods exist. SHERLOCK4HAT 331 overcomes these limitations. We have shown that SHERLOCK4HAT detection is not limited by 332 geography or time after sampling, it is easy to set up, does not require sophisticated equipment 333 and it is adapted for high-throughput applications (fluorescence readout) or individual testing 334 (LFA), making it versatile for both surveillance at reference centers and PoC testing. The 335 SHERLOCK4HAT diagnostic can be run in 1 h 30 min for a one-step reaction (at 4.5 € if coupled 336 to a commercial LFA), or 2 h 30 min for a two-step reaction (at 2.8 €), and these costs would be 337 notably reduced with an in-house manufactured strip for LFA. 338

One limitation for SHERLOCK4HAT, as for any molecular diagnostic method, is the NA extraction step. Several extraction methods coupled to a CRISPR-based diagnostic reaction have been published (8, 47, 48), but remained to be tested in the context of HAT diagnostics. For highthroughput surveillance using SHERLOCK4HAT, automated NA extraction systems can be implemented with higher reproducibility, reduced hand-on time and no cross-contamination. Manual extraction methods, although more time consuming, showed an increased analytical sensitivity which is consistent with previous studies (*49*). As an RNA-based diagnostic, SHERLCOCK is limited by the increased sensitivity of RNA to nuclease degradation, which can affect the sensitivity of the test if the clinical specimens are not stored properly. Nucleic acid stabilization buffers or Flinders Technology Associates (FTA) cards to transport and store the samples can be used to attenuate these limitations. It should be noted that RNA is a better indicator of active infections than DNA (*35*), making SHERLOCK4HAT a valuable tool for assessing treatment outcome.

352 The bio-banked clinical samples used here to validate SHERLOCK4HAT did not allow proper analysis of sensitivity for gHAT patients. 44% of confirmed gHAT patient samples were negative 353 with SHERLOCK, and 53% were negative using standard qPCR analysis. The discrepancy 354 between our results compared to the original in-field diagnostic is most probably due to the 355 deterioration of the NA in these samples, that were stored at -80°C for more than 10 years without 356 preservative (41). Low parasitemia is typical in gHAT infections, thus any NA degradation could 357 have a dramatic effect on detection using molecular techniques. T. b. rhodesiense infections have 358 higher parasitemia, hence deterioration of NA in the samples might have a lower impact in the 359 diagnostic sensitivity, which is evident given the robust sensitivity using rHAT SHERLOCK. The 360 lower sensitivity observed with the TgSGP target (42.5%) could be attributed to a selective 361 degradation of the target RNA and / or to a differential expression of the TgSGP gene in these 362 samples, since the analytical sensitivity of SHERLOCK for 7SLRNA and TgSGP was similar. 363 From the 62 negative control samples, 7 tested positive for TgSGP compared to 1 or 0 for 364 7SLRNA SHERLOCK or qPCR, respectively. This reduced specificity needs to be interrogated 365 further. 366

As we move towards the elimination phase of gHAT, if not to the post-elimination phase in 367 several countries, SHERLOCK4HAT is a viable alternative to currently used diagnostics at the 368 PoC. Optimization of the one-pot reaction to meet the sensitivity requirements for HAT diagnosis, 369 lyophilization of the reaction components and field-friendly NA extraction methods will be 370 required before large-scale deployment. Sensitivity could also be improved using a combination 371 of 7SLRNA, TgSGP and SRA targets in a multiplex SHERLOCK4HAT diagnostic kit that would 372 allow the specific detection of the three subspecies of T. brucei at the same time in a single 373 reaction, thereby reducing the full diagnostic cost and making the technology more adapted for 374 horizontal epidemiological studies, including in animal reservoirs. In total, SHERLOCK4HAT 375 provides a readily adaptable diagnostic method for HAT allowing for PoC diagnosis, mass 376 screening and epidemiological surveillance. 377

#### 378 Materials and Methods

#### 379 LwCas13a protein expression and purification

Plasmid pC013-Twinstrep-SUMO-huLwCas13a (Addgene plasmid # 90097) (*11*) was used to express LwCas13a in *Escherichia coli* Rosseta<sup>TM</sup> 2(DE3) pLySs competent cells. Cell pellet was lysed with supplemented lysis buffer (20 mM Tris-HCl pH8.0, 500 mM NaCl, 1 mM DTT, 100 mg lysozyme, 200U Deoxyribonuclease I) and LwCas13a protein was purified from the cleared supernatant as described in (*13*) (fig. S10).

#### **Target selection and crRNA and RPA primer design**

Target genes were selected as either unique or based on their conservation between Trypanosoma 386 publicly available using literature and data from TriTrvpDB 387 SDD (https://tritrypdb.org/tritrypdb/app). Candidate genes were aligned using BLAST with the 388 Trypanosomatidae (taxid:5654) nucleotide collection database from the National Center for 389 Biotechnology Information (NBCI). Alignments to ensure conservation of targets across the 390 Trypanozoon subgenus or exclusivity between T. brucei subspecies was performed using Clustal 391 392 Omega. Data available in TriTrypDB was used to identify SNPs found in different field isolates in the target genes 7SLRNA, SODB1 and TgSGP (50). To identify the SNPs in the SRA gene, the 393 sequence variants AF097331, AJ345057, AJ345057 (22, 26) were aligned using Clustal Omega 394 and visualized in Jalview 2.11.1. RPA primers and crRNAs were designed to cover the conserved 395 regions of the selected genes and outside of regions containing single nucleotide polymorphisms 396 (SNPs). BLAST analysis with the nucleotide collection of all available genomes was performed 397 to ensure RPA primers and crRNAs specific alignment. A 5' T7 RNA polymerase promoter 398 sequence (5'GAAATTAATACGACTCACTATAGGG) overhang was added to the RPA forward 399 primers for in vitro transcription (IVT) during SHERLOCK reaction. The amplicons generated 400 during RPA reactions are between 130-160 nt length. We used a 28 nt crRNA spacer for all 401 guides in this study except for cr7SLbs which is 26 nt. The spacer sequence is joined to a 5' direct 402 repeat (DR) to generate the complete crRNA. To facilitate amplification from DNA templates a 403 T7 RNA polymerase promoter sequence was added upstream of the crRNA (spacer + DR + T7404 promoter 5'>3'). RPA primer, crRNA and DNA IVT template sequences are detailed in 405 supplementary table 1. SNPs identified for each target gene are included in supplementary table 2. 406

#### 407Target RNA and crRNA synthesis and purification

408 To produce the crRNA's, DNA IVT templates and T7-3G oligonucleotide were purchased from ThermoFisher. crRNAs were synthesized as described in (13) with the following modifications. 409 DNA IVT template (10 µM) and T7-3G oligonucleotide (10 µM) were annealed in standard Tag 410 buffer (1x) by performing a 5-minute denaturation, followed by slow cooling (ramp rate was 411 adjusted to 0.13°C/s) of the reaction to 4°C in a PCR thermocycler (BioRad). IVT was performed 412 using the HiScribe<sup>™</sup> T7 Quick High Yield RNA Synthesis Kit (NEB E2050S), where 10 µL of 413 annealed reaction were mixed with 10 µL of NTP buffer mix, 2 µL of T7 RNA polymerase mix 414 and 17 µL of RNase free water. The reaction was incubated for 6 hours at 37°C followed by 15 415 minutes of DNase I digestion to remove DNA template. Purification of crRNA was done with 416 Agencourt RNAClean XP beads following the manufacturer's protocol and crRNA concentration 417 was adjusted to 300 ng/µL. Urea Poly-Acrylamid Gel Electrophoresis were used to confirm the 418 purity and correct size of crRNAs. 419

120 ng of RNA from *T. b. gambiense* ELIANE strain for TgSGP or 40 ng of RNA from *T. b.* 121 *rhodesiense* EATRO strain for *SRA* RNA production were retro-transcribed using pT19 122 oligonucleotide and SuperScript IV Retro Transcriptase (Thermo Fisher) following standard 123 protocols. cDNAs were purified with Ampure XP (A63880) following manufacturer instructions 124 and eluted in 30 µL of nuclease free water. *TgSGP* and *SRA* were amplified from 5 µL of cDNA,

using TgSGP-FL-F and TgSGP-FL-R primers or SRA-FL-F and SRA-FL-R primers, 425 respectively. For 7SLRNA production, the 7SLRNA gene was amplified from 120 ng of T. b. 426 brucei Lister 427 genomic DNA, using 7SLb-UP-F.6 and 7SLb-FL-R primers. The PCR 427 amplification reaction was as follows: 0.2 mM dNTPs, 0.5 µM of each primer, 5 µL of DNA, 428 0.75 µL of DMSO, 0.5 µL of Phusion DNA polymerase in HF buffer 1X in a 25 µL final volume 429 and was run according to standard PCR settings. A T7 RNA polymerase promoter sequence 430 overhang was included in each forward primer for in vitro transcription. IVT of the amplified 431 genes was performed using the HiScribe<sup>™</sup> T7 Quick High Yield RNA Synthesis Kit following 432 manufacturer's instructions and the reaction incubated for 3 hours at 37°C followed by 15 433 minutes of DNaseI digestion. The single stranded RNA was purified using Agencourt RNAClean 434 XP beads following the manufacturer's protocol. In vitro transcribed RNAs were sequenced and 435 Urea Poly-Acrylamid Gel Electrophoresis were used to confirm the purity and correct size of the 436 target RNAs. Primer sequences used in this section are specified in supplementary table 6. 437

#### 438 **RNA isolation from cultured parasites**

T. b. brucei Lister 427 bloodstream stage cells were cultured in HMI-11 medium at 37.4°C with 5% CO<sub>2</sub>. RNA was harvested at 1x 10<sup>6</sup> cell/mL. *T. b. gambiense* ELIANE and *T. b. rhodesiense* EATRO cell pellets were a gift from Annette MacLeod and *L. major* cells were a gift from Gerald Spaeth. Total RNA from *T. b. brucei* Lister 427, *T. b. gambiense* ELIANE strain, *T. b. rhodesiense* EATRO strain, *L. major* and Human embryonic kidney (HEK) 293T cells, was extracted with the RNeasy Mini kit (Qiagen).

# Simulated samples and total nucleic acid (TNA) extraction from blood, buffy coat and dry blood spots (DBS)

Blood from healthy human donors was provided by ICAReB platform (Clinical Investigation & 147 Access to Research Bioresources) in the Center for Translational Science, at the Institut Pasteur 448 (Paris) (51). All participants gave written informed consent in the frame of the healthy volunteers 449 Diagmicoll cohort (Clinical trials NCT 03912246) after approval of the CPP Ile-de-France I 450 Ethics Committee (2009, April 30th). Whole blood was extracted in BD Vacutainer<sup>TM</sup> Glass ACD 451 Solution Tubes and immediately processed. To determine the performance of 7SLRNA 452 SHERLOCK in whole blood, buffy coat and DBS,  $2x10^5$  T. b. brucei Lister 427 parasites were 453 spiked into 20 mL of human blood followed by 1:10 dilution to simulate parasitemia of 10 and 1 454 parasites/µL. Nine drops of 50 µL of each dilution of the simulated infected blood and non-455 infected blood were dried on Whatman 903<sup>TM</sup> Cards and stored at RT for 24 hours until 456 processed. Three tubes of 500 µL of whole blood were snap-frozen and stored at -80°C for 72 457 hours. To obtain the buffy coat, 12 mL of each simulated infected blood dilution and non-infected 458 blood were centrifuged at 1800 g for 10 minutes without brake, at 4°C to prevent RNA 459 degradation. Three tubes of 125 µL of buffy coat for each dilution were snap-frozen and stored at 460 -80°C for 72 hours. TNA extraction from DBS was performed with the Nucleospin Triprep kit 461 (Macherey-Nagel). For that, 6 x 6 mm punches were incubated with 350 µL of RP1 buffer and 3.5 462  $\mu$ L of  $\beta$ -mercaptoethanol at 37°C for 30 minutes in agitation (1000 rpm). The instructions from 463 the manufacturer were followed from this step onwards. DNA and RNA were eluted together in 464

40  $\mu$ L of nuclease free water. TNAs from whole blood and buffy coat simulated samples was 466 conducted with Maxwell RSC DNA blood kit (PROMEGA AS1400). The samples were pre-467 processed with 300  $\mu$ L of lysis buffer and 30  $\mu$ L of Proteinase K solution, vortexed for 10 468 seconds and incubated at 56°C for 20 minutes. The volume was transferred to the Maxwell 469 Cartridge and the kit protocol was run in the automated Maxwell RSC system. TNAs were eluted 470 in 60  $\mu$ L of elution buffer. Extractions for each dilution and type of sample were done in 471 triplicate.

#### **Determination of analytical sensitivity**

To determine the analytical sensitivity of *7SLRNA* SHERLOCK limiting dilutions of *T. b. brucei* 473 Lister 427 parasites were spiked into un-infected human blood. TNAs were extracted from whole 474 blood and buffy coat with Maxwell RSC DNA blood kit as detailed above. Three replicates of 475 each dilution were assessed by SHERLOCK and the estimated LoD was determined as the lowest 476 concentration where 3 out of 3 replicates were positive. The analytical sensitivity was confirmed 477 in buffy coat by using 20 replicates of 0.66X, 1X and 1.5X the estimated LoD concentration. The 478 analytical sensitivity was determined as the concentration where 95% of the samples gave 479 positive results. 480

#### 481 **Optimization of TNA extraction methods**

482 To compare different TNA extraction methods from DBS, sheep blood was spiked with T. b. brucei Lister 427 parasites at limiting dilutions (1000-1 parasites/µL). Drops of 50 µL were dried 483 into Whatman 903<sup>TM</sup> Cards and stored at RT for 24 hours. For TNA extraction with RNeasy mini 484 and micro kits (Qiagen) 3 x 6 mm punches were resuspended with 370 µL of RLT buffer with 3.7 485  $\mu$ L of  $\beta$ -mercaptoethanol and incubated at 37°C for 30 minutes with agitation (1000 rpm). The 486 487 punches and liquid were transferred into a QIAshredder column and spun at maxim speed for 1 minute. The homogenized sample was then processed according to manufacturer's instructions 488 489 without DNaseI digestion. DNA and RNA were eluted in the same fraction with 10  $\mu$ L (RNeasy micro kit) or 30 µL (RNeasy mini kit) of nuclease-free water. For TNA extraction with the 490 Nucleospin Triprep kit (Macherey-Nagel) 3 x 6 mm punches were resuspended with 350 µL of 491 492 RP1 buffer with 3.5 µL of b-mercaptoethanol and incubated at 37°C for 30 minutes in agitation (1000 rpm). The instructions from the manufacturer were followed from this step onwards and 493 DNA and RNA were eluted together in 40 µL of nuclease free water. Maxwell RSC DNA blood 494 kit (AS1400), Maxwell RSC SimplyRNA blood kit (AS1380) and RNeasy mini kit (Qiagen) were 495 used to extract TNA from 250 µL or 125 µL of human buffy coat spiked with limiting dilutions of 496 497 T. b. brucei Lister 427 parasites.

#### 498 Field isolated samples

The RNA used in this study was derived from 57 field isolates representing different *Trypanosoma* species, subspecies and strains. The collection contained 50 *T. b. gambiense* group 1 (46 bloodstream forms + 4 insect forms), 1 *T. b. gambiense* group 2, 2 *T. b. rhodesiense*, 1 *T. b. brucei*, 1 *T. equiperdum* and 2 *T. evansi* strains or clones. They were kindly provided by Nick 503 Van Reet and Philippe Büscher (Institute of Tropical Medicine [ITM], Antwerp, Belgium) (40).

The RNA was kept at -80 and the concentration normalized to 5  $ng/\mu L$ . Three microliters of input

<sup>505</sup> material were used for each SHERLOCK analysis.

## 506 Clinical samples

507 Clinical samples in this study were obtained from the WHO HAT Specimen biobank (41). They 508 included buffy coats from 48 individuals living in *T. b. gambiense* endemic areas who were 509 negative for gHAT by serology and parasitology, 50 patients with confirmed gHAT at stage 1, 48 510 patients with confirmed gHAT at stage 2, 20 individuals living in *T. b. rhodesiense* endemic areas 511 who were negative for rHAT by serology and parasitology and 19 patients with confirmed rHAT 512 at stage 2. TNA were extracted from 125  $\mu$ L of sample using the Maxwell RSC Blood DNA kit as 513 detailed above. The material was eluted in 50  $\mu$ L of elution buffer.

# 514 SHERLOCK two-step reaction

For the isothermal amplification step, TwistAmp Basic kit (TwistDx) was used according to 515 manufacturer's instructions with the following modifications. For each reaction, 3 uL of input 516 total nucleic acids (TNA) were incubated with 480 nM of each RPA primer (240 nM for TgSGP 517 RPA primers), Reaction buffer 1X, 2.2 U of Transcriptor (Roche), 1.5 U of Murine RNase 518 inhibitor (NEB) and 14 mM MgOAc and 0.22 pellet of TwistAmp Basic kit, in a final volume of 519 11 µL. Reaction condition were optimized using different RPA primer concentrations (120, 240 520 or 480 nM) and MgOAc concentrations (14, 22 or 30 mM). The reactions were run using Hard-521 shell thin wall 96 well PCR Plates, sealed with Microseal 'F' Foil Seals (BioRad). Plates were 522 523 incubated in a heating block set to 42°C with thermoregulated lid. After a 5 minutes incubation, the plates were agitated for 15 seconds and the incubation resumed for 40 min. For the LwCas13a 524 detection step, 1 µL of the previous reaction was incubated with 20 mM HEPES pH 6.5, 9 mM 525 MgCl<sub>2</sub>, 1 mM rNTP mix (NEB), 126 ng of LwCas13a, 2 U of Murine RNase inhibitor (NEB), 25 526 U of NxGen T7 RNA Polymerase (Biosearch technology), 10 ng of crRNA and 125 nM of 527 RNaseAlert probe V2 (Invitrogen) in a final volume of 20 µL. The reactions were run in 3 or 4 528 replicates in 384-well plates, F-bottom, uClear bottom, black, sterile, with lid (Greiner). The 529 incubations were maintained at 37°C in the TECAN plate reader INFINITE 200 PRO Option M 530 PLEX and the fluorescence was recorded at an initial time point and after 2 h 30 min or 3 hours. 531 For the lateral flow assay (LFA) readout Milenia HybriDetect strips were used and the 532 RNaseAlert probe was substituted for 10 pmol of LF-RNA reporter 533 (/56-FAM/rUrUrUrUrU/3Bio) and was incubated likewise. Following this, the SHERLOCK 534 reaction was mixed with 80 µL of a PEG-based CRISPR-optimized Lateral Flow Assay Buffer 535 (provided by Milenia Biotec GmbH, Germany). The strip was dipped in the mix and the results 536 537 were interpreted after 5 min.

# 538 SHERLOCK one-step reaction

539 For the single step SHERLOCK assay, 8  $\mu$ L of input NA were mixed with 1 pellet of TwistAmp

- 540 Basic kit, 20 mM HEPES pH 8, 60 mM KCl, 5% PEG-8000, 132 ng of LwCas13a in 1mM Tris-
- 541 HCl pH 7.5, 12 mM NaCl, 0.1% glycerol, 125 nM of RNaseAlert probe, 2 U/µL of ProtoScript II

RT (NEB), 0.1 U/ $\mu$ L of RNase H (NEB), 1 U/ $\mu$ L of NxGen T7 RNA Polymerase (Biosearch technology), 455 nM of each RPA primer, 10 nM of crRNA and 14 mM of MgOAc in a final volume of 107.5  $\mu$ L. For each technical replicate, 20  $\mu$ L of the mix were transferred to a 384-well plate, F-bottom,  $\mu$ Clear bottom, black, sterile, with lid (Greiner). The incubations were done in the TECAN plate reader as described above. The fluorescence was monitored over 2 h 30 min at 37°C with a 30 min interval between acquisitions.

#### 548 **Quantitative PCR analysis**

549 TNA were analyzed by qPCR using Luna Universal qPCR MasterMix (NEB). The qPCR amplification mix contained 1 µL template and 0.4 µM of each primer (Tb177bp F/R). Reactions 550 were run in triplicate in a Hard-shell PCR Plates 96 well, thin wall, which were sealed with 551 Microseal 'B' Seals (BioRad). All experiments were run on a CFX96 Touch Real-time Detection 552 system with a C1000 Touch Thermal cycler (Bio-Rad), using the following PCR cycling 553 conditions: 50°C for 5 min, 95°C for 10□min, then 40 cycles of 95°C for 15 sec and 66°C for 554 1 min (fluorescence intensity data collected at the end of the last step), followed by a 555 temperature gradient between 66°C and 95°C. The last step was used for dissociation analysis of 556 the PCR product to monitor the amplicon identity. For that, the melt temperature of the amplicons 557 from clinical samples was compared with that from T. brucei control nucleic acids. Sequence of 558 primers in this section are listed in supplementary table 6. 559

#### 560 Data analysis

We used the fluorescence given by the negative control, where water is used as input material, as 561 the background fluorescence. To calculate the background-subtracted fluorescence intensities in a 562 given multi-well plate, we subtracted the background fluorescence from each sample fluorescence 563 at final time point. To calculate the fold-change over background fluorescence in a given multi-564 well plate, sample fluorescence was divided by background fluorescence at final time point. For 565 the optimization of the TNA extraction methods, fluorescence values were reported as fold-566 changes from the initial baseline fluorescence intensity by dividing the fluorescence value at last 567 time point by the value at initial time point. Baseline initial fluorescence and background 568 fluorescence differ between runs. Therefore, it was more effective to compare fold-change over 569 background fluorescence. 570

571 For the analysis of the clinical samples the following ratios were calculated for every target 572 assessed:

• Negative template controls Ratio (Rntc) = Fold-change over the initial baseline fluorescence:

$$Rntc = \frac{FCntc \ t = 3h}{FCntc \ t = 0}$$

Mean *Rntc* = mean *Rntc* of 3 replicates

Where FC, fluorescence readout

• Positive template controls Ratio (Rpc) and sample Ratio (Rsample ) = Fold-change over the background fluorescence at time 3h. Background fluorescence is given by the negative template control reaction:

$$Rpc = \frac{FCpc \ t = 3h}{FCntc \ mean \ t = 3h}$$

Mean Rpc = mean Rpc of 3 replicates

 $Rsample = \frac{FCsample \ t = 3h}{FCntc \ mean \ t = 3h}$ 

*Mean* Rsample = mean *Rsample* of 3 replicates

Where FC, fluorescence readout

Fluorescence ratios from positive and negative samples were computed by receiver operating characteristic (ROC) curve analysis for determining test positivity thresholds (fig. S11).

For qPCR, mean Ct values of 3 technical replicates were reported. A read was considered positive when the Ct value was lower than the established cut-off and the identity of the amplicon of these assays was confirmed by dissociation analysis (specific melt temperature  $\pm$  0.5 degrees). The specific melt temperature for each amplicon was calculated by dissociation analysis of the qPCR amplicons using dilution series of TNA from cultured parasites. The Ct value cut-off was determined using cumulative distribution analysis (fig. S12).

All plots and statistical analyses were performed with GraphPad Prism 9.1.2.

# 589 Acknowledgments

We would like to thank the following people for kindly providing parasite strains and / or parasite NAs used in this study: Annette MacLeod (University of Glasgow, Glasgow, UK), Gerald Spaeth and Artur Scherf (Institut Pasteur, Paris, France), Philippe Büscher and Nick Van Reet (Institute of Tropical Medicine, Antwerp, Belgium).

**Funding:** This project has received a funding from the Institut Pasteur to BR and LG (PTR-175 SHERLOCK4HAT) and from the French Government's Investissement d'Avenir program Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (LabEx IBEID). NS was supported by funding from the Institut Pasteur (PTR-175 SHERLOCK4HAT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions: NS, BR and LG conceived and designed the experiments. NS, ADH performed the experiments. NS, BR and LG analyzed the data. MNU, BLP, BR and LG contributed reagents, materials and analysis tools. NS, BR and LG wrote the paper.

503 **Competing interests:** The authors declare that they have no competing interests.

579

504 **Data and materials availability:** All data are available in the main text or the supplementary 505 materials.

506

**Ethics statement:** Blood from healthy human donors was provided by ICAReB platform (Clinical Investigation & Access to Research Bioresources) in the Center for Translational Science, at the Institut Pasteur (Paris). All participants gave written informed consent in the frame of the healthy volunteers Diagmicoll cohort (Clinical trials NCT 03912246) after approval of the CPP Ile-de-France I Ethics Committee (2009, April 30th). For the WHO HAT Specimen biobank samples, approval was given by the WHO Ethical Review Committee, each national ethical committee where samples were taken and the national Ministries of Health.

514

### 515 **References**

- P. Büscher, G. Cecchi, V. Jamonneau, G. Priotto, Human African trypanosomiasis. *The Lancet.* 390, 2397–2409 (2017).
- J. R. Franco, G. Cecchi, G. Priotto, M. Paone, A. Diarra, L. Grout, P. P. Simarro, W. Zhao,
   D. Argaw, Monitoring the elimination of human African trypanosomiasis at continental
   and country level: Update to 2018. *Plos Negl Trop Dis.* 14, e8261 (2020).
- 3. P. Büscher, S. Deborggraeve, How can molecular diagnostics contribute to the elimination
  of human African trypanosomiasis? *Expert Rev Mol Diagn.* 15, 607-615 (2015).
- S. Deborggraeve, P. Büscher, Recent progress in molecular diagnosis of sleeping sickness.
   *Expert Rev Mol Diagn.* 12, 719–730 (2012).
- 5. M. Camara, A. M'mah Soumah, H. Ilboudo, C. Travaillé, C. Clucas, A. Cooper, N.-R. K.
  Swar, O. Camara, I. Sadissou, E. Calvo Alvarez, A. Crouzols, J.-M. Bart, V. Jamonneau,
  M. Camara, A. Macleod, B. Bucheton, B. Rotureau, Extravascular dermal trypanosomes in
  suspected and confirmed cases of gambiense human African trypanosomiasis. *Clinical Infectious Diseases.* 73, 12–20 (2021).
- 6. P. Capewell, K. Atkins, W. Weir, V. Jamonneau, M. Camara, C. Clucas, N.-R. K. Swar, D.
  M. Ngoyi, B. Rotureau, P. Garside, A. P. Galvani, B. Bucheton, A. Macleod, Resolving the
  apparent transmission paradox of African sleeping sickness. *Plos Biol.* 17, e3000105
  (2019).
- M. Aliee, M. J. Keeling, K. S. Rock, Modelling to explore the potential impact of
   asymptomatic human infections on transmission and dynamics of African sleeping
   sickness. *PLoS Comput Biol.* 17, e1009367 (2021).
- 8. R. A. Lee, H. de Puig, P. Q. Nguyen, N. M. Angenent-Mari, N. M. Donghia, J. P. Mcgee,
  J. D. Dvorin, C. M. Klapperich, N. R. Pollock, J. J. Collins, Ultrasensitive CRISPR-based
  diagnostic for field-applicable detection of Plasmodium species in symptomatic and
  asymptomatic malaria. *PNAS.* 41, 25722-25731 (2020).
- 9. C. H. Cunningham, C. M. Hennelly, J. T. Lin, R. Ubalee, R. M. Boyce, E. M. Mulogo, N.
  Hathaway, K. L. Thwai, F. Phanzu, A. Kalonji, K. Mwandagalirwa, A. Tshefu, J. J.
  Juliano, J. B. Parr, A novel CRISPR-based malaria diagnostic capable of Plasmodium
  detection, species differentiation, and drug-resistance genotyping. *EBioMedicine*. 68,
  e103415 (2021).
- M. M. Kaminski, O. O. Abudayyeh, J. S. Gootenberg, F. Zhang, J. J. Collins, CRISPR based diagnostics. *Nature Biomedical Engineering*. 5, 643–656 (2021).
- J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee, P. Essletzbichler, A. J. Dy, J. Joung, V.
  Verdine, N. Donghia, N. M. Daringer, C. A. Freije, C. Myhrvold, R. P. Bhattacharyya, J.

- Livny, A. Regev, E. V. Koonin, D. T. Hung, P. C. Sabeti, J. J. Collins, F. Zhang, Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science*. **356**, 438–442 (2017).
- J. S. Gootenberg, O. O. Abudayyeh, M. J. Kellner, J. Joung, J. J. Collins, F. Zhang,
   Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6.
   *Science*. 360, 439–444 (2018).
- M. J. Kellner, J. G. Koob, J. S. Gootenberg, O. O. Abudayyeh, F. Zhang, SHERLOCK:
   nucleic acid detection with CRISPR nucleases. *Nature Protocols*. 14, 2986–3012 (2019).
- A. Tambe, A. East-Seletsky, G. J. Knott, J. A. Doudna, M. R. O'Connell, RNA binding
  and HEPN-nuclease activation are decoupled in CRISPR-Cas13a. *Cell Reports*. 24, 1025–
  1036 (2018).
- M. Berberof, D. Pérez-Morga, E. Pays, A receptor-like flagellar pocket glycoprotein
   specific to Trypanosoma brucei gambiense. *Mol Biochem Parasitol.* 113, 127-138 (2001).
- W. Gibson, L. Nemetschke, J. Ndung'u, Conserved sequence of the TgsGP gene in Group
  1 Trypanosoma brucei gambiense. *Infect Genet Evol.* 10, 453–458 (2010).
- 17. C. Felu, J. Pasture, E. Pays, D. Pérez-Morga, Diagnostic potential of a conserved genomic
   rearrangement in the trypanosoma brucei gambiense-specific TgSGP locus. *Am J Trop Med Hyg.* 76, 922–929 (2007).
- 18. C. de Greef, R. Hamers, The serum resistance-associated (SRA) gene of Trypanosoma
   brucei rhodesiense encodes a variant surface glycoprotein-like protein. *Mol Biochem Parasitol.* 68, 277–284 (1994).
- 570 19. C. de Greef, H. Imberechts, G. Matthyssens, N. Van Meirvenne, R. Hamers, A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. *Mol Biochem Parasitol.* 36, 169-176 (1989).
- S. C. Welburn, K. Picozzi, E. M. Fèvre, P. G. Coleman, M. Odiit, M. Carrington, I.
  Maudlin, Identification of human-infective trypanosomes in animal reservoir of sleeping
  sickness in Uganda by means of serum-resistance-associated (SRA) gene. The *Lancet.* 358,
  2017–2019 (2001).
- M. Radwanska, M. Chamekh, L. Vanhamme, F. Claes, S. Magez, E. Magnus, P. de Baetselier, P. Büscher, E. Pays, The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. *Am J Trop Med Hyg.* 67, 684–690 (2002).
- W. Gibson, T. Backhouse, A. Griffiths, The human serum resistance associated gene is
   ubiquitous and conserved in Trypanosoma brucei rhodesiense throughout East Africa. *Inf Genet Evol.* 1, 207-214 (2002).
- O. Balmer, J. S. Beadell, W. Gibson, A. Caccone, Phylogeography and taxonomy of
   Trypanosoma brucei. *PLoS Negl Trop Dis.* 5, e961 (2011).
- H. Van Xong, L. Vanhamme, M. Chamekh, C. E. Chimfwembe, J. Van Den Abbeele, A.
  Pays, N. Van Meirvenne, R. Hamers, P. de Baetselier, E. Pays, A VSG expression siteassociated gene confers resistance to human serum in Trypanosoma rhodesiense. *Cell.* 95, 839–846 (1998).
- L. Vanhamme, H. Renauld, L. Lecordier, P. Poelvoorde, J. Van Den Abbeele, E. Pays, The
   Trypanosoma brucei reference strain TREU927/4 contains T. brucei rhodesiense-specific
   SRA sequences, but displays a distinct phenotype of relative resistance to human serum.
   *Mol Biochem Parasitol.* 135, 39–47 (2004).
- J. D. Milner, S. L. Hajduk, Expression and localization of serum resistance associated
   protein in Trypanosoma brucei rhodesiense. *Mol Biochem Parasitol.* 104, 271–283 (1999).
- M. Camara, O. Camara, H. Ilboudo, H. Sakande, J. Kaboré, L. N'Dri, V. Jamonneau, B.
   Bucheton, Sleeping sickness diagnosis: Use of buffy coats improves the sensitivity of the
   mini anion exchange centrifugation test. *Tropical Medicine and International Health.* 15,
   796–799 (2010).

- P. Büscher, D. M. Ngoyi, J. Kaboré, V. Lejon, J. Robays, V. Jamonneau, N. Bebronne, W.
  Van Der Veken, S. Biéler, Improved models of mini anion exchange centrifugation
  technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness
  diagnosis and staging. *PLoS Negl Trop Dis.* **3**, e471 (2009).
- D. R. Moser, G. A. Cook, D. E. Ochs, C. P. Bailey, M. R. McKane, J. E. Donelson,
   Detection of trypanosoma congolense and trypanosoma brucei subspecies by DNA
   amplification using the polymerase chain reaction. *Parasitology*. 99, 57–66 (1989).
- P. Mitashi, E. Hasker, D. M. Ngoyi, P. P. Pyana, V. Lejon, W. Van der Veken, P. Lutumba,
  P. Büscher, M. Boelaert, S. Deborggraeve, Diagnostic accuracy of loopamp Trypanosoma
  brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples. *PLoS Negl Trop Dis.* 7, e2504 (2013).
- C. F. Alfred Compaoré, H. Ilboudo, J. Kaboré, J. W. Kaboré, O. Camara, M. Bamba, H.
  Sakande, M. Koné, M. Camara, D. Kaba, A. M. Gaston Belem, S. Deborggraeve, P.
  Büscher, B. Bucheton, V. Lejon, V. Jamonneau, Analytical sensitivity of loopamp and
  quantitative real-time PCR on dried blood spots and their potential role in monitoring
  human African trypanosomiasis elimination. *Experimental Parasitology*. 219, e108014
  (2020).
- S. Becker, J. R. Franco, P. P. Simarro, A. Stich, P. M. Abel, D. Steverding, Real-time PCR
  for detection of Trypanosoma brucei in human blood samples. *Diagn Microbiol Infect Dis*.
  50, 193–199 (2004).
- C. M. Mugasa, T. Laurent, G. J. Schoone, P. A. Kager, G. W. Lubega, H. D. F. H. Schallig,
   Nucleic acid sequence-based amplification with oligochromatography for detection of
   Trypanosoma brucei in clinical samples. *Journal of Clinical Microbiology*. 47, 630–635
   (2009).
- P. González-Andrade, M. Camara, H. Ilboudo, B. Bucheton, V. Jamonneau, S.
   Deborggraeve, Diagnosis of trypanosomatid Infections; targeting the spliced leader RNA. J
   *Mol Diagn.* 16, 400–404 (2014).
- S. Deborggraeve, V. Lejon, R. A. Ekangu, D. M. Ngoyi, P. P. Pyana, M. Dard Ilunga, J. P.
  Mulunda, P. Büscher, Diagnostic accuracy of PCR in gambiense sleeping sickness
  diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study. *Plos Negl Trop Dis.* 5, e972 (2011).
- 36. M. Radwanska, P. Claes, S. Magez, E. Magnus, D. Pérez-Morga, E. Pays, P. Büscher,
  Novel primer sequences for Polymerase Chain Reaction-based detection of Trypanosoma
  brucei gambiense. *Am J Trop Med Hyg.* 67, 289–295 (2002).
- 37. Z. K. Njiru, A. S. J. Mikosza, T. Armstrong, J. C. Enyaru, J. M. Ndung'u, A. R. C.
   Thompson, Loop-mediated isothermal amplification (LAMP) method for rapid detection of
   Trypanosoma brucei rhodesiense. *PLoS Negl Trop Dis.* 2, e147 (2008).
- J. Arizti-Sanz, C. A. Freije, A. C. Stanton, B. A. Petros, C. K. Boehm, S. Siddiqui, B. M.
  Shaw, G. Adams, T. S. F. Kosoko-Thoroddsen, M. E. Kemball, J. N. Uwanibe, F. V.
  Ajogbasile, P. E. Eromon, R. Gross, L. Wronka, K. Caviness, L. E. Hensley, N. H.
  Bergman, B. L. MacInnis, C. T. Happi, J. E. Lemieux, P. C. Sabeti, C. Myhrvold,
  Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. *Nature Communications.* 11, 5921 (2020).
- O. O. Abudayyeh, J. S. Gootenberg, S. Konermann, J. Joung, I. M. Slaymaker, D. B. T.
  Cox, S. Shmakov, K. S. Makarova, E. Semenova, L. Minakhin, K. Severinov, A. Regev, E.
  S. Lander, E. V. Koonin, F. Zhang, C2c2 is a single-component programmable RNAguided RNA-targeting CRISPR effector. *Science*. 353, aaf5573 (2016).
- N. Van Reet, P. Patient Pyana, S. Dehou, N. Bebronne, S. Deborggraeve, P. Büscher,
   Single nucleotide polymorphisms and copy-number variations in the Trypanosoma brucei

- repeat (TBR) sequence can be used to enhance amplification and genotyping of
   Trypanozoon strains. *PLOS ONE*. 16, e0258711 (2021).
- J. R. Franco, P. P. Simarro, A. Diarra, J. A. Ruiz-Postigo, J. G. Jannin, The human African
  trypanosomiasis specimen biobank: A necessary tool to support research of new
  diagnostics. *PLoS Negl Trop Dis.* 6, e1571 (2012).
- 42. S. Deborggraeve, F. Claes, T. Laurent, P. Mertens, T. Leclipteux, J. C. Dujardin, P.
   Herdewijn, P. Büscher, Molecular dipstick test for diagnosis of sleeping sickness. *Journal of clinical microbiology*. 44, 2884–2889 (2006).
- C. M. Mugasa, G. J. Schoone, R. A. Ekangu, G. W. Lubega, P. A. Kager, H. D. F. H.
  Schallig, Detection of Trypanosoma brucei parasites in blood samples using real-time nucleic acid sequence-based amplification. *Diagn Microbiol Infect Dis.* 61, 440–445 (2008).
- 44. Z. K. Njiru, A. S. J. Mikosza, E. Matovu, J. C. K. Enyaru, J. O. Ouma, S. N. Kibona, R. C.
  A. Thompson, J. M. Ndung'u, African trypanosomiasis: Sensitive and rapid detection of
  the sub-genus Trypanozoon by loop-mediated isothermal amplification (LAMP) of parasite
  DNA. *International Journal for Parasitology*. 38, 589–599 (2008).
- K. Picozzi, E. M. Fèvre, M. Odiit, M. Carrington, M. C. Eisler, I. Maudlin, S. C. Welburn,
  Sleeping sickness in Uganda: A thin line between two fatal diseases. *British Medical Journal.* 331, 1238–1241 (2005).
- 768 46. J. So, *et al.*, https://doi.org/10.1101/2021.09.09.459620 (2021).
- 47. C. Myhrvold, C. A. Freije, J. S. Gootenberg, O. O. Abudayyeh, H. C. Metsky, A. F. Durbin, M. J. Kellner, A. L. Tan, L. M. Paul, L. A. Parham, K. F. Garcia, K. G. Barnes, B. Chak, A. Mondini, M. L. Nogueira, S. Isern, S. F. Michael, I. Lorenzana, N. L. Yozwiak, B. L. MacInnis, I. Bosch, L. Gehrke, F. Zhang, P. C. Sabeti, Field-deployable viral diagnostics using CRISPR-Cas13. *Science*. 320, 444-448 (2018).
- 48. J. Joung, A. Ladha, M. Saito, N.-G. Kim, A. E. Woolley, M. Segel, R. P. J. Barretto, A.
  Ranu, R. K. Macrae, G. Faure, E. I. Ioannidi, R. N. Krajeski, R. Bruneau, M.-L. W. Huang,
  X. G. Yu, J. Z. Li, B. D. Walker, D. T. Hung, A. L. Greninger, K. R. Jerome, J. S.
  Gootenberg, O. O. Abudayyed, F. Zhang, Detection of SARS-CoV-2 with SHERLOCK
  one-pot testing. *N Engl J Med.* 383, 14992-1494 (2020).
- J. Dunlop, C. K. Thompson, S. S. Godfrey, R. C. A. Thompson, Sensitivity testing of
  trypanosome detection by PCR from whole blood samples using manual and automated
  DNA extraction methods. *Experimental Parasitology*. 146, 20–24 (2014).
- 50. W. Weir, P. Capewell, B. Foth, C. Clucas, A. Pountain, P. Steketee, N. Veitch, M. Koffi, T.
  De Meeû, J. Kaboré, M. Camara, A. Cooper, A. Tait, V. Jamonneau, B. Bucheton, M.
  Berriman, A. MacLeod, Population genomics reveals the origin and asexual evolution of
  human infective trypanosomes. *eLIFE*. 5, e11473 (2015).
- P. Esterre, A. Ait-Saadi, L. Arowas, S. Chaouche, N. Corre-Catelin, C. Fanaud, H. Laude,
  V. Mellon, V. Monceaux, G. Morizot, I. Najjar, C. Ottone, B. L. Perlaza, B. Rimbault, L.
- 788 Sangari, M. N. Ungeheuer, The ICAReB Platform: A human biobank for the Institut
- Pasteur and beyond. *Open Journal of Bioresources*. 7, 1 (2020) BB-0033-00062, BBMRI
   A0203/ 21 distributions/ last access: 2021, 06, 29.
- 791
- 792 793

#### 794

795

#### 796 Figure Legends

797

<sup>798</sup> Fig. 1. Detection of *Trypanosoma brucei* sspp. RNA with SHERLOCK. (A), Schematic

799 overview of the SHERLOCK assay principle. Two-step SHERLOCK reaction is performed after TNA extraction. First, target NA is retro-transcribed and/or amplified during the RT-/RPA 300 reaction at 42°C. Second, the amplified target is *in vitro* transcribed and detected by Cas13a that 301 cuts the RNA reporter upon target activation. Finally, the released reporter can be quantified with 302 a fluorescence plate reader and / or with a LFA, making the methodology suitable for both mass 303 screening and PoC testing. Panel created using BioRender.com. (B), Schematic showing selected 304 target genes, RPA primer pairs and CRISPR guides. (C), Specificity of 7SLRNA, TgSGP and SRA 305 in a two-step SHERLOCK reaction using RNA from T. b. brucei Lister 427, T. b. gambiense 306 ELIANE strain, T. b. rhodesiense EATRO strain, Plasmodium falciparum, Leishmania major and 307 Human Embryonic Kidney (HEK) T cells. Fluorescence was measured after 150 mins. 308 Background subtracted fluorescence of 4 technical replicates is plotted as mean +/- standard 309 deviation (SD). a.u., arbitrary units. (D), Limits of detection of the 7SLRNA, TgSGP and SRA 310 targets in two-step SHERLOCK reactions. Dilution series of total RNA extracted from cultured 311 parasites. T. b. brucei Lister 427, T. b. gambiense ELIANE strain, T. b. rhodesiense EATRO 312 313 strain were used for the 7SLRNA, TgSGP and SRA SHERLOCK reactions, respectively. Fluorescence was measured after 150 mins. Coloured circles represent the mean ± SD of 4 314 technical replicates. Two-tailed Student's t test between fluorescence outputs of sample vs. no-315 template control. \*\*\* p<0.001, \*\*\*\* p<0.0001. a.u., arbitrary units. ns, non-significant. (E), Limit 316 of detection of 7SLRNA, TgSGP and SRA in a two-step SHERLOCK reaction with a lateral flow 317 assay (LFA) read-out after 5 mins. (F), Limits of detection of two-step vs. single-step 7SLRNA 318 319 SHERLOCK reactions on total RNAs from T. b. brucei Lister 427. Fluorescence was measured after 150 mins. Blue bars represent the mean background subtracted fluorescence  $\pm$  SD of 4 320 technical replicates shown as open circles. a.u., arbitrary units. (G), Kinetics of the single step 321 reaction in F. Each coloured circle represents the average of 4 technical replicates ± SD. Two-322 tailed Student's t test between fluorescence outputs of sample vs. no-template control. \*\*\* 323 p<0.001, \*\*\*\* p<0.0001. a.u., arbitrary units. ns, non-significant. 324 325

326

Fig. 2. Validation of SHERLOCK4HAT using field isolated samples. SHERLOCK detection of 7SLRNA,  $T_gSGP$  or SRA targets using RNA extracted from field isolated trypanosome strains.  $T_gSGP$  (left panel) and SRA (right panel) target readouts are plotted against 7SLRNA readouts in fold change over background fluorescence. Each dot represents the average readout of 4 technical replicates. The thresholds for each target (red lines) were determined using ROC curve analyses of positive and negative sample data. In brackets, after the name of the species, number of strains analysed.

334 335

Fig. 3. Performance of SHERLOCK4HAT on dried blood spots, whole blood and buffy coat. 336 (A), A comparison of the performance of the 7SLRNA SHERLOCK on trypanosome RNA 337 extracted from dried blood spots (DBS), whole blood and buffy coat. All experiments were done 338 in 4 replicates from a single pool of simulated infected blood. Fold changes over background 339 fluorescence were plotted as mean +/- SD. Student's two-tailed t test between readout of sample 340 vs. no-template control. \*\*\* p<0.001, \*\*\*\* p<0.0001. (B), Samples with known parasitemia were 341 used to assess the analytical sensitivity of the 7SLRNA SHERLOCK. Three replicates of each 342 343 dilution were tested. The tentative limit of detection (LoD) was the lowest concentration where 3/3 replicates were positive for the test. The detection threshold (red line) was determined using 344 ROC curve analyses of positive and negative sample data. (C), The LoD was confirmed by using 345 samples at 0.66X, 1X and 1.5X the estimated LoD concentration of the buffy coat only. The 346

experiment was done on 20 replicates and the LoD was determined to be the concentration at which 95% of the samples were positive for the test. The detection threshold (red line) was determined using ROC curve analyses of positive and negative sample data. (**D**), Tables summarizing the results in panels B and C. Performance near the LoD of *7SLRNA* SHERLOCK with whole blood and buffy coat samples.

Fig. 4. Validation of SHERLOCK4HAT diagnostic using bio-banked clinical samples. (A), 754 7SLRNA

SHERLOCK analysis of 160 gHAT qPCR positive (left) and negative (right) buffy coat samples 355 obtained from human subjects in gHAT endemic and non-endemic regions. Each dot indicates one 356 sample analysed by both 7SLRNA SHERLOCK and Tb177bp-repeats-qPCR. The dashed red line 357 is the threshold above which samples were considered positive for SHERLOCK. The dot colours 358 indicate the classification according to the original diagnosis in the field. (B), Concordance tables, 359 sensitivity and specificity of 7SLRNA SHERLOCK for detection of trypanosome NA in buffy coat 360 samples from individuals in gHAT endemic and non-endemic regions. qPCR indicates samples 361 that were analysed by Tb177bp-repeats-qPCR. nC, negative controls from non-endemic regions, 362 gC, gHAT negative endemic controls. (C), 7SLRNA SHERLOCK analysis of 53 rHAT qPCR 363 positive (left) and negative (right) buffy coat samples obtained from human subjects in rHAT 364 endemic and non-endemic regions. Each dot indicates one sample analysed by both 7SLRNA 365 SHERLOCK and *Tb177bp-repeats-qPCR*. The dashed red line is the threshold above which 366 samples were considered positive for SHERLOCK. The dot colours indicate the classification 367 368 according to the original diagnostic in the field. (D), Concordance tables, sensitivity and specificity of 7SLRNA SHERLOCK for detection of trypanosome NA in buffy coat samples from 369 individuals in rHAT endemic and non-endemic regions. qPCR indicates samples that were 370 analysed by Tb177bp-repeats-qPCR. nC, non-endemic negative controls, rC, rHAT endemic 371 negative controls. (E), TgSGP and SRA SHERLOCK discriminate between T. b. gambiense and T. 372 b. rhodesiense NA in patients. All gHAT and rHAT patient samples positive for 7SLRNA were 373 plotted according to their TgSGP and SRA SHERLOCK results. The thresholds for each target (red 374 lines) were determined using ROC curve analyses of positive and negative sample data. 375

376

352

#### Table 1. RPA primers and crRNA guides selected in this study.

378

#### **SHERLOCK Reaction**

# Figure 1



Figure 2



Figure 3



Simulated parasitemia (parasite/µL)	Total positives in blood	Total positives in buffy coat
100	3/3	3/3
10	3/3	3/3
1	2/3	3/3
0.5	1/3	NA
0.25	0/3	NA
0.1	1/3	1/3
0	0/3	0/3
рс	3/3	3/3
nc	0/3	0/3

Simulated parasitemia (parasite/µL)	Total positives	Percentage of detection
1.5	20/20	100%
1	19/20	95%
0.66	10/20	50%

Figure 4

Total

#### Samples from gHAT patients



В

A

Samples from gHAT patients: SHERLOCK vs qPCR					
7SLRNA SHERLOCK	Positive for qPCR	Negative for qPCR	Total	Concordance	Sensitivit
Positive	40	16	56	40+97/160 (85.6%)	40/47 (85.1%)
Negative	7	97	104		

113

47

Samples from gHAT patients: SHERLOCK vs field diagnosis							
7SLRNA SHERLOCK	nC	gC	gHAT stage 1	gHAT stage 2	Total	Concordance	Specificity
Positive	1	0	27	28	56	13+48+27+28/160 (72.5%)	
Negative	13	48	23	20	104		13+48/14+48 (98.4%)
Total	14	48	50	48	160		

160

С

#### Samples from rHAT patients



rHAT stage 2
 rHAT-endemic negative controls
 non-endemic negative controls







Trypanosoma species Target (accession number)	RPA forward primer with <i>T7 promoter</i> overhang 5'>3'	RPA reverse primer 5'>3'	crRNA sequence 5'>3' (DR + spacer 28nt)
Trypanozoon 7SLRNA (Tb927.8.2861)	<i>GAAATTAATACGACTCACTATAGG</i> <i>G</i> CGGAGCGCATTGCTCTGTAACC TTC	CCACTTTAACGGCGC GAGAACGCC	GAUUUAGACUACCCCAAAAACGAAGGG GACUAAAACCAACACCGACACGCAACC AAGCAGAACA
<i>T. brucei gambiense</i> TgSGP (FN555988.1)	<i>GAAATTAATACGACTCACTATAGG</i> <i>G</i> TTT GACAGCATGGGAGATGCAACTC GCAAG	CAAGTCCGTGACAGC CTTGCCCGTTCCCGC	GAUUUAGACUACCCCAAAAACGAAGGG GACUAAAACAAAUGGCUUCCAGCUUCC GCUGUGCUAG
T. brucei rhodesiense SRA (AF097331)	<i>GAAATTAATACGACTCACTATAGG</i> <i>G</i> AA AAGCAAACTCGTATCAATCCAA GAGT	CCCTTGTCTTTGTCGT CGCCAATTGCGT	GAUUUAGACUACCCCAAAAACGAAGGG GACUAAAACGGCGACCUGCUGCUUGCA GCUUUCAGUG

Table 1. RPA primers and crRNAs selected in this study